![]() |
市場調查報告書
商品編碼
2024954
G蛋白偶聯受體(GPCR)市場規模、佔有率、趨勢和預測:按產品類型、檢測類型、應用和地區分類,2026-2034年G-Protein Coupled Receptors (GPCRs) Market Size, Share, Trends and Forecast by Product, Assay Type, Application, and Region, 2026-2034 |
||||||
2025年全球G蛋白偶聯受體(GPCR)市場規模為38億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到60億美元,2026年至2034年的複合年成長率(CAGR)為4.98%。北美市場佔據主導地位,2025年市佔率超過40.3%。北美GPCR市場成長的主要驅動力在於其在製藥領域的強勁研發投入、許多大型生物技術公司的存在以及慢性病盛行率的上升。先進的醫療基礎設施和完善的法規結構也進一步推動了該地區在藥物研發和GPCR標靶治療開發方面GPCR市場佔有率的擴展。
G蛋白偶聯受體(GPCRs)是人類基因組編碼的最大蛋白質家族。它們是訊號分子,負責將訊號傳遞給細胞,在將細胞外刺激轉化為細胞內反應的過程中發揮著至關重要的作用。 GPCRs位於細胞膜上,負責多種生理過程。作為細胞表面受體,GPCRs如同“接收盒”,接收以脂質、醣類、光能、胜肽和蛋白質形式存在的訊息。這些受體被廣泛用於治療多種疾病,包括發炎性疾病、代謝紊亂、心臟病、癌症和單基因疾病。因此,GPCRs也存在於許多生物的細胞膜上,包括哺乳動物、植物、微生物和無脊椎動物。
全球藥物研發領域對G蛋白偶聯受體(GPCR)的日益廣泛應用是推動市場成長的主要動力。癌症患者數量的不斷成長以及心血管和呼吸系統疾病等文明病的日益增多,促使GPCR在新藥研發中得到廣泛應用。此外,GPCR位於細胞表面,可由多種化學或生物藥品調控,並廣泛參與多種生理過程,這也是推動市場成長的另一個因素。同時,將自動化和創新技術融入藥物篩檢流程,以提高治療藥物的生產能力,也是推動市場成長的重要因素。此外,有效藥物發現方法的顯著進步,例如受體結構的最佳化和新藥配方計算方法的改進,也促進了市場成長。此外,GPCR在腫瘤學各個方面(包括侵襲、轉移和血管重塑)的廣泛應用,也顯著推動了市場成長。最後,GPCR在闡明轉移和腫瘤生長以及開發有效治療方法的應用日益廣泛,正在對市場成長產生積極影響。其他預計推動市場成長的因素包括廣泛的研發活動、各種自動化技術的進步、環Adenosine腺苷(cAMP)的廣泛應用,以及主導在生物技術和生物製藥領域實施的各項措施。
The global G-protein coupled receptors (GPCRs) market size was valued at USD 3.8 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 6.0 Billion by 2034, exhibiting a CAGR of 4.98% during 2026-2034. North America dominated the market, holding a significant market share of over 40.3% in 2025. North America led the GPCRs market due to strong pharmaceutical R&D investment, the presence of major biotech companies, and the rising prevalence of chronic diseases. Advanced healthcare infrastructure and supportive regulatory frameworks further contributed to the region's G-protein coupled receptors (GPCRs) market share in both drug discovery and GPCR-targeted therapeutics development.
G-protein-coupled receptors (GPCRs) are the largest protein family encoded by the human genome. They are signal-transducing molecules that transmit signals to cells and play a key role in converting an extracellular stimulus into intracellular responses. They are located in the cell membrane and are responsible for all physiological processes. GPCRs are cell surface receptors that act like an inbox for messages in the form of lipids, sugars, light energy, peptides, and proteins. These receptors are widely used in the treatment of various diseases, such as inflammatory disorders, metabolic imbalances, cardiac disorders, cancer, and monogenic disorders. As a result, GPCRs are also found in the cell membranes of several organisms, including mammals, plants, microorganisms, and invertebrates.
The increasing adoption of GPCRs in drug discovery across the globe is one of the key factors driving the market growth. In line with this, the widespread utilization of GPCRs in the development of novel pharmaceuticals due to the rising number of cancer cases and lifestyle-related diseases, such as cardiovascular infections and respiratory difficulties, are favoring the market growth. Moreover, the extensive application of GPCRs in several physiological processes as they can be modulated by a wide range of chemical or biological agents due to their cell-surface location is acting as another growth-inducing factor. Apart from this, the integration of automation and innovative technologies with drug development screening procedures to improve their capabilities in therapeutic production is providing an impetus to the market growth. Furthermore, significant developments in effective drug discovery methods, such as advancements in the computational approaches to streamline receptor structure and formulation of new drugs, are propelling the market growth. Additionally, the widespread adoption of GPCRs in oncology and various aspects of cancer biology, such as invasion, migration, and vascular remolding, is providing a considerable boost to the market growth. Besides this, the increasing utilization of GPCRs for decoding metastasis and growth of tumors and developing effective lines of treatment is positively influencing the market growth. Other factors, including extensive research and development (R&D) activities, various automation improvements, the widespread adoption of cyclic Adenosine Monophosphate (cAMP), and the implementation of various government initiatives in the biotechnology and biopharmaceutical sector are anticipated to drive the market growth.
The publisher provides an analysis of the key trends in each segment of the global G-protein coupled receptors (GPCRs) market, along with forecasts at the global, regional, and country level from 2026-2034. Our report has categorized the market based on product, assay type, and application.
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for G-protein coupled receptors (GPCRs). Some of the factors driving the North America G-protein coupled receptors (GPCRs) market included rising number of cancer cases, extensive research and development (R&D) activities, and various automation improvements.
The report has also provided a comprehensive analysis of the competitive landscape in the global G-protein coupled receptors (GPCRs) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abcam plc, Becton Dickinson and Company, Enzo Biochem Inc., Eurofins DiscoverX Products LLC, HD Biosciences Co. Ltd. (WuXi AppTec), Merck KGaA, Molecular Devices LLC (Danaher Corporation), PerkinElmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., etc.